Latest News

Glassia (more than) half full: "Bioworld Today" features Kamada as its top-story

Mar. 20, 2017

This week's top- story is about Kamada's GVHD clinical program and other interesting clinical implications of its AAT pipeline.

Kamada Announces Collaboration with Massachusetts General Hospital for Proof of Concept Study Evaluating Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation

Feb. 21, 2017

The conpany announced today a collaboration with Massachusetts General Hospital (MGH) to conduct a proof of concept study evaluating the potential benefit of the Company’s Liquid Alpha-1 Antitrypsin (AAT) on liver preservation.

Upcoming Events

Kamada will host a Research and Development Day to highlight Graft versus Host Disease (GvHD)

Mar. 3, 2017 / New York

Kamada will host a Research and Development Day to highlight Graft versus Host Disease (GvHD) in New York City on March 3 from 12:00pm to 1:30pm Eastern Time.

This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only.  Please RSVP in advance if you plan to attend, as space is limited. To reserve a spot, please reply to this email or contact LifeSci Advisors, LLC at Mac@LifeSciAdvisors.com.  A live and archived webcast of the event, with slides, will be available at http://lifesci.rampard.com/20170303/reg.jsp.

The meeting will feature a presentation by key opinion leaders H. Joachim Deeg, MD (Fred Hutchinson Cancer Research Center) and David M. Gelmont, MD (formerly at Shire/Baxalta), who will discuss the current treatment landscape for GvHD in bone marrow transplant patients and the unmet medical need for patients who develop acute GvHD. Both KOLs will be available to answer questions following the lunch.

Kamada management will provide an overview of the Company’s ongoing clinical development work with their liquid form of Alpha-1 Antitrypsin (AAT) to treat acute Graft versus Host Disease, including published data to-date, and the company's clinical strategy moving forward.

Kamada to participate in PPTA Congress, Prague 2017

Mar. 14-15, 2017

Every year, policymakers, regulators, industry leaders, physicians, scientists, and patient representatives from around the globe come together for the plasma protein therapeutics industry's premier European event—the International Plasma Protein Congress (IPPC).

Past Event

Kamada to Host Fiscal Year 2016 Financial Results Conference Call on February 6

Feb. 2, 2017 / Conference Call

Direct webcast link

Kamada  announced today that it will release financial results for the fiscal year ended December 31, 2016 prior to the open of the U.S. financial markets on Monday, February 6, 2017.
Kamada management will host an investment community conference call on Monday,
February 6 at 8:30 a.m. Eastern time to discuss these results and answer questions.
Shareholders and other interested parties may participate in the conference call by dialing
888-452-4034 (from within the U.S.), 1 80 924 5905 (from Israel), or 719-457-2087
(International) and entering the conference identification number: 5468241. The call will
also be webcast live on the internet on the Company’s website at www.kamada.com.
A replay of the call will be accessible two hours after its completion through February 20
by dialing 844-512-2921 (from within the U.S.) or 412-317-6671 (from outside the U.S.)
and entering the conference identification number: 5468241. The call will also be archived
for 90 days on the Company’s website at www.kamada.com.